Dravet syndrome (DS) is a catastrophic epilepsy of childhood, characterized by cognitive 1 impairment, severe seizures and increased risk for sudden unexplained death in epilepsy 2 (SUDEP). Although refractory to conventional antiepileptic drugs, emerging preclinical and 3 clinical evidence suggests that modulation of the endocanniboid system could be therapeutic in 4 these patients. Here we used a validated zebrafish model of DS, scn1lab homozygous mutants, 5
to screen a commercially available library containing 370 synthetic cannabinoid (SC) 6 compounds for compounds effective in reducing spontaneous seizures. Primary phenotype-7 based screening was performed using a locomotion-based assay in 96-well plates, and a 8 secondary local field potential recording assay was then used to confirm suppression of 9 electrographic epileptiform events. Identified SCs with anti-seizure activity, in both assays, 1 0
included five SCs structurally classified as indole-based cannabinoids: JWH 018 N-(5-1 1 chloropentyl) analog, JWH 018 N-(2-methylbutyl) isomer, 5-fluoro PB-22 5-1 2 hydroxyisoquinoline isomer, 5-fluoro ADBICA, and AB-FUBINACA 3-fluorobenzyl isomer. 1 3
Our approach demonstrates that two-stage phenotype-based screening in a zebrafish model of DS 1 4 successfully identifies synthetic cannabinoids with anti-seizure activity, and supports further 1 5 investigation of SCs for refractory epilepsies. 1 6 glucocorticoid receptor are similar to those in human. These properties combined with the ease 2 3 1 of large-scale pharmacological screening make larval zebrafish a good model system for 2 3 2 investigating drug targets. A recent study 31 , limited only to locomotion assay read-outs in larval 2 3 3 zebrafish, reported a synergistic effect of Δ -9-tetrahydrocannabinol (THC) and cannabidiol 2 3 4 (CBD) on hyperactive behaviors.
Unfortunately, these studies failed to include 2 3 5 electrophysiology measures of efficacy and were limited to only these two compounds. Here we 2 3 6 screened 370 different synthetic cannabinoids in a locomotion assay at two different drug 2 3 7 concentrations, initially identifying 20 compounds as exerting potential therapeutic benefit. 2 3 8
With repeated biological replicates, newly sourced compound re-tests and sensitive secondary 2 3 9 electrophysiologay assays, we narrowed this initial list to five SCs that were classified as 2 4 0 effective in suppressing spontaneous seizures (behavioral and electrographic) in scn1lab 2 4 1 mutants. This scientifically stringent two-stage approach further validates the selectivity of our 2 4 2 screening strategy as only 1.3% of all SCs tested were identified as positive hits. A caveat of this 2 4 3 strategy is that pharmacokinetic data for how these SCs are absorbed, distributed or metabolized 2 4 4 in larval zebrafish is not available which would suggest an error in false negative designations. 2 4 5
Interestingly, as several of these SCs are classified as indole-derivatives these data also suggest a 2 4 6 potential target not recognized in previous preclinical studies. Indole-derived cannabinoids have 2 4 7 strong binding affinity for the 5HT 2B receptor 32 . This serotonin receptor subtype was recently 2 4 8 identified by our group as potentially mediating the anti-seizure effects of clemizole 33 . Taken 2 4 9 together, a convergence of evidence now exists to suggest that activation of a serotonin 2B 2 5 0 receptor is a potential target for DS therapy. Although further preclinical studies investigating SCs identified here are warranted, a note of 2 5 3 caution needs to be extended to clinical translation of these data. Substantial evidence of serious 2 5 4 adverse effects accompany these compounds. These include, and may not be limited to, panic 2 5 5 attacks, memory distortions, paranoia, psychotic reactions, disorganized behavior, and suicidal 2 5 6 thoughts 34, 35 . Reports of acute ischemic stroke 36, 37 , seizures 38, 39 , and sudden death 40-42 with SCs 2 5 7 are not uncommon. In particular, indole-and indazole-based SCs are associated with clinical 2 5 8 signs of reduced consciousness, paranoia and seizures in humans 43 . Acknowledging these 2 5 9 limitations, the current studies provide tools for further preclinical research investigating the 2 6 0 anti-seizure potential of the endocannabinoid signaling system. This information is valuable for 2 6 1 investigators and clinician-scientists interested in the potential benefits of cannabinoid receptor 2 6 2 agonists for intractable seizure disorders. This work was supported from NINDS R01 grants no. NS079214 and NS103139 (S.C.B).
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